2
Participants
Start Date
September 14, 2021
Primary Completion Date
May 4, 2022
Study Completion Date
March 14, 2023
Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma
Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
Treatment for Small Cell Lung Cancer
Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
Markey Cancer Center, University of Kentucky, Lexington
National Center for Advancing Translational Sciences (NCATS)
NIH
Charles Kunos
OTHER